Medical Advocates for Social Justice
Conference Abstract
from the
1st European HIV Drug Resistance Workshop
Cercle Municipal, Luxembourg

March 06- 08, 2003
 

 
The impact of concomitant antiblastic chemotherapy
and HAART on HIV-viraemia and resistance profile in
HIV-infected patients with non-Hodgkin’s lymphoma 
[Abstract 2.13]
C Simonelli, S Zanussi, R.Cinelli, L Dal Maso, G di Gennaro,
M D’Andrea, G Nasti, M Spina, E Vaccher, P De Paolo,
U. Tirelli.
 

 National Cancer Institute, Aviano (PN) – Italy

  
Share this Abstract with a Colleague
Objective and design
The aim of this study was to investigate the impact of chemotherapy (CT) on the viral load and the development of HIV resistance in HIV patients affected by Non-Hodgkin’s Lymphomas (NHL) treated with concomitant HAART. HIV patients with systemic, intermediate/high grade NHL diagnosed and treated at the Aviano Cancer Center were enrolled in a study protocol  in order to evaluate HIV replication and genotyping under concomitant therapy with antiblastic drugs and HAART.

Methods
Patients were  considered evaluable for HIV-viraemia and genotyping if they had received at least 3 cycles of CT+HAART. Genotyping was performed at  baseline and  when virological failure occurred. The resistance interpretation was performed by the Stanford Beta Test software and by VircoNET analysis

Results
We assessed the virological response to HAART in 35 HIV-NHL patients treated with CHOP+HAART and in 26 CD20-positive HIV patients with NHL, treated with Rituximab and CDE. Only 9 patients met the virological failure criteria. The genotyping analysis and carried out in the "HIV failure patients" and the consequent resistance interpretation demonstrated that CT might induce new mutations, but does not change pre-existing resistance patterns.

Conclusions
Our data show that the CT+HAART is feasible and HAART can maintain the HIV virological response in the majority of the patients even in this setting. 
 
Main New/Newsworthy Non-Hodgkin’s Lymphoma Data Luxembourg Conference Index      

The impact of concomitant antiblastic chemotherapy
and HAART on HIV-viraemia and resistance profile in
HIV-infected patients with non-Hodgkin’s lymphoma 
A Medical Advocates for Social Justice Update